KR101916443B1 - Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 - Google Patents
Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 Download PDFInfo
- Publication number
- KR101916443B1 KR101916443B1 KR1020157005099A KR20157005099A KR101916443B1 KR 101916443 B1 KR101916443 B1 KR 101916443B1 KR 1020157005099 A KR1020157005099 A KR 1020157005099A KR 20157005099 A KR20157005099 A KR 20157005099A KR 101916443 B1 KR101916443 B1 KR 101916443B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyrrolo
- formula
- pyridin
- benzo
- methanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(CC1*)C(*)CN1C(c(cc(c(N*)c1*)N)c1I)=O Chemical compound *C(CC1*)C(*)CN1C(c(cc(c(N*)c1*)N)c1I)=O 0.000 description 3
- REUNVCLBHFFYFH-JGVFFNPUSA-N CC(C)(C)OC(N[C@@H](CNCC1)[C@@H]1O)=O Chemical compound CC(C)(C)OC(N[C@@H](CNCC1)[C@@H]1O)=O REUNVCLBHFFYFH-JGVFFNPUSA-N 0.000 description 1
- HOFXZLPRBKAASR-CYBMUJFWSA-N CC(C)(C)OC(N[C@H](CCC1)CN1C(c(cc1)cc(N)c1NC)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)CN1C(c(cc1)cc(N)c1NC)=O)=O HOFXZLPRBKAASR-CYBMUJFWSA-N 0.000 description 1
- PXJXCBYHGJEEJH-UHFFFAOYSA-N CC(CCC(C1)N)N1C(c1cc(OC)c2[n](C)c(-c([n]3CC4CC4)cc4c3nccc4)nc2c1)=O Chemical compound CC(CCC(C1)N)N1C(c1cc(OC)c2[n](C)c(-c([n]3CC4CC4)cc4c3nccc4)nc2c1)=O PXJXCBYHGJEEJH-UHFFFAOYSA-N 0.000 description 1
- JJTNDYXEBOKKOM-UHFFFAOYSA-N CC(CCC(C1)NC(OC(C)(C)C)=O)N1C(c(cc1OC)cc2c1[n](C)c(-c([n]1CC3CC3)cc3c1nccc3)n2)=O Chemical compound CC(CCC(C1)NC(OC(C)(C)C)=O)N1C(c(cc1OC)cc2c1[n](C)c(-c([n]1CC3CC3)cc3c1nccc3)n2)=O JJTNDYXEBOKKOM-UHFFFAOYSA-N 0.000 description 1
- CUZDPEBQVSHMAS-QGZVFWFLSA-N CC[n](c(-c1nc(cc(cc2)C(N(CCC3)C[C@@H]3N)=O)c2[n]1C)c1)c(nc2)c1cc2OC Chemical compound CC[n](c(-c1nc(cc(cc2)C(N(CCC3)C[C@@H]3N)=O)c2[n]1C)c1)c(nc2)c1cc2OC CUZDPEBQVSHMAS-QGZVFWFLSA-N 0.000 description 1
- BNEALNTWWPLJNG-UHFFFAOYSA-N O=Cc([n]1CC2CC2)cc2c1nccc2 Chemical compound O=Cc([n]1CC2CC2)cc2c1nccc2 BNEALNTWWPLJNG-UHFFFAOYSA-N 0.000 description 1
- HHKFHQWRPIALDR-UHFFFAOYSA-N O=Cc1cc(cncc2)c2[nH]1 Chemical compound O=Cc1cc(cncc2)c2[nH]1 HHKFHQWRPIALDR-UHFFFAOYSA-N 0.000 description 1
- BOVXSSYSWCHQMX-UHFFFAOYSA-N O=Cc1cc(cncc2)c2[n]1S(c1ccccc1)(=O)=O Chemical compound O=Cc1cc(cncc2)c2[n]1S(c1ccccc1)(=O)=O BOVXSSYSWCHQMX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/064649 WO2014015905A1 (en) | 2012-07-26 | 2012-07-26 | 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150038438A KR20150038438A (ko) | 2015-04-08 |
| KR101916443B1 true KR101916443B1 (ko) | 2018-11-08 |
Family
ID=49996626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157005099A Active KR101916443B1 (ko) | 2012-07-26 | 2012-07-26 | Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9127003B2 (https=) |
| EP (1) | EP2877467B1 (https=) |
| JP (1) | JP6063567B2 (https=) |
| KR (1) | KR101916443B1 (https=) |
| CN (1) | CN104470919B (https=) |
| AU (1) | AU2012386257B2 (https=) |
| BR (1) | BR112015001545B1 (https=) |
| CA (1) | CA2879341C (https=) |
| CY (1) | CY1118524T1 (https=) |
| DK (1) | DK2877467T3 (https=) |
| ES (1) | ES2609126T3 (https=) |
| HR (1) | HRP20161530T1 (https=) |
| HU (1) | HUE033294T2 (https=) |
| IN (1) | IN2014KN02935A (https=) |
| LT (1) | LT2877467T (https=) |
| PL (1) | PL2877467T3 (https=) |
| PT (1) | PT2877467T (https=) |
| RS (1) | RS55684B1 (https=) |
| RU (1) | RU2611010C2 (https=) |
| SI (1) | SI2877467T1 (https=) |
| SM (2) | SMT201700052T1 (https=) |
| WO (1) | WO2014015905A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180005250A (ko) * | 2015-05-21 | 2018-01-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Pad4 억제제로서의 벤조이미다졸 유도체 |
| AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| CA3015482A1 (en) * | 2016-02-23 | 2017-08-31 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of pad4 |
| CN107188867A (zh) * | 2016-03-14 | 2017-09-22 | 中国科学院天津工业生物技术研究所 | 精氨酸脱亚氨酶4的抑制剂 |
| WO2018022897A1 (en) * | 2016-07-27 | 2018-02-01 | Padlock Therapeutics, Inc. | Covalent inhibitors of pad4 |
| US11026937B2 (en) | 2016-09-12 | 2021-06-08 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of PAD4 |
| US11208386B2 (en) | 2016-12-02 | 2021-12-28 | University Of Massachusetts | Inhibitors of protein arginine deiminases (PADs) and methods of preparation and use thereof |
| CN108689946B (zh) * | 2017-04-12 | 2022-10-18 | 中国科学院上海药物研究所 | 2-取代硫基乙酰胺类化合物及其制备方法和应用 |
| RU2764243C2 (ru) * | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| AU2018352142B2 (en) * | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| TWI762769B (zh) * | 2018-02-26 | 2022-05-01 | 大陸商藥捷安康(南京)科技股份有限公司 | 肽醯精胺酸脫亞胺酶抑制劑及其用途 |
| MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
| CN112839648B (zh) | 2018-06-07 | 2025-04-04 | 达萨玛治疗公司 | Sarm1抑制剂 |
| MX2021001471A (es) * | 2018-08-08 | 2021-04-28 | Bristol Myers Squibb Co | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |
| JP7447080B2 (ja) | 2018-08-08 | 2024-03-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐａｄ４阻害剤としての置換チエノピロール |
| MX2021001565A (es) * | 2018-08-08 | 2021-04-19 | Bristol Myers Squibb Co | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). |
| US20220348562A1 (en) * | 2018-08-08 | 2022-11-03 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
| CN109369513B (zh) * | 2018-11-20 | 2020-08-25 | 都创(上海)医药科技有限公司 | 一种fbdd常用分子片段的制备方法 |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| US12448358B2 (en) * | 2019-07-03 | 2025-10-21 | University Of Massachusetts | Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof |
| TW202115083A (zh) * | 2019-09-27 | 2021-04-16 | 大陸商南京藥捷安康生物科技有限公司 | 肽醯精胺酸脫亞胺酶抑制劑及其用途 |
| WO2021158840A1 (en) * | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
| TW202140477A (zh) * | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| CN111265526B (zh) * | 2020-04-09 | 2021-03-19 | 黑龙江中医药大学 | 一种治疗胃癌的药物及其制备方法 |
| WO2021222353A1 (en) | 2020-04-30 | 2021-11-04 | Gilead Sciences, Inc. | Macrocyclic inhibitors of peptidylarginine deiminases |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| EP4215534A4 (en) | 2020-09-18 | 2024-10-02 | Carna Biosciences, Inc. | AMINE DERIVATIVE |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| WO2022140390A1 (en) | 2020-12-22 | 2022-06-30 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| US20250136607A1 (en) | 2021-11-15 | 2025-05-01 | Regor Pharmaceuticals, Inc. | Pad4 inhibitors and use thereof |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| CN119604287A (zh) * | 2022-05-26 | 2025-03-11 | 细胞基因公司 | 杂环pad4抑制剂 |
| AU2023387505B2 (en) * | 2022-11-24 | 2026-03-05 | Helios Huaming Biopharma Co., Ltd. | Selenium containing heterocycle compounds and use thereof |
| KR20260041867A (ko) | 2023-07-21 | 2026-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법 |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063822A1 (en) | 2004-09-23 | 2006-03-23 | Weinstein David S | Indole inhibitors of 15-lipoxygenase |
| WO2009042092A1 (en) | 2007-09-25 | 2009-04-02 | Merck & Co., Inc. | 2-aryl or heteroaryl indole derivatives |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU570439B2 (en) | 1983-03-28 | 1988-03-17 | Compression Labs, Inc. | A combined intraframe and interframe transform coding system |
| HU219900B (hu) | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Mért dózist adagoló inhalálóberendezés |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| ES2253930T3 (es) * | 1998-09-18 | 2006-06-01 | ABBOTT GMBH & CO. KG | 4-aminopirrolopirimidinas como inhibidores de quinasa. |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| AU778042B2 (en) * | 1999-10-19 | 2004-11-11 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2001047922A2 (en) | 1999-12-24 | 2001-07-05 | Aventis Pharma Limited | Azaindoles |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003000690A1 (en) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthesis of heterocyclic compounds employing microwave technology |
| CN1901958B (zh) | 2003-11-03 | 2011-03-09 | 葛兰素集团有限公司 | 流体分配装置 |
| CA2546192C (en) | 2003-11-17 | 2010-04-06 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| FR2862971B1 (fr) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| JP2011521961A (ja) | 2008-05-28 | 2011-07-28 | ワイス・エルエルシー | ３−置換−１Ｈ−インドール化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成 |
| RU2011106786A (ru) * | 2008-07-23 | 2012-08-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы пиразолопиридинкиназы |
| MY159575A (en) * | 2009-04-02 | 2017-01-13 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
-
2012
- 2012-07-26 KR KR1020157005099A patent/KR101916443B1/ko active Active
- 2012-07-26 PL PL12740581T patent/PL2877467T3/pl unknown
- 2012-07-26 CA CA2879341A patent/CA2879341C/en active Active
- 2012-07-26 SI SI201230769A patent/SI2877467T1/sl unknown
- 2012-07-26 EP EP12740581.9A patent/EP2877467B1/en active Active
- 2012-07-26 SM SM20170052T patent/SMT201700052T1/it unknown
- 2012-07-26 JP JP2015523426A patent/JP6063567B2/ja active Active
- 2012-07-26 DK DK12740581.9T patent/DK2877467T3/en active
- 2012-07-26 AU AU2012386257A patent/AU2012386257B2/en active Active
- 2012-07-26 RU RU2014152456A patent/RU2611010C2/ru active
- 2012-07-26 ES ES12740581.9T patent/ES2609126T3/es active Active
- 2012-07-26 IN IN2935KON2014 patent/IN2014KN02935A/en unknown
- 2012-07-26 PT PT127405819T patent/PT2877467T/pt unknown
- 2012-07-26 WO PCT/EP2012/064649 patent/WO2014015905A1/en not_active Ceased
- 2012-07-26 HR HRP20161530TT patent/HRP20161530T1/hr unknown
- 2012-07-26 BR BR112015001545-0A patent/BR112015001545B1/pt active IP Right Grant
- 2012-07-26 HU HUE12740581A patent/HUE033294T2/en unknown
- 2012-07-26 LT LTEP12740581.9T patent/LT2877467T/lt unknown
- 2012-07-26 US US14/416,937 patent/US9127003B2/en active Active
- 2012-07-26 CN CN201280074868.5A patent/CN104470919B/zh active Active
- 2012-07-26 RS RS20170121A patent/RS55684B1/sr unknown
-
2015
- 2015-08-03 US US14/816,246 patent/US9518054B2/en active Active
-
2016
- 2016-11-15 US US15/352,340 patent/US9833449B2/en active Active
-
2017
- 2017-01-24 SM SM201700052T patent/SMT201700052B/it unknown
- 2017-01-27 CY CY20171100128T patent/CY1118524T1/el unknown
- 2017-11-20 US US15/817,562 patent/US10039755B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063822A1 (en) | 2004-09-23 | 2006-03-23 | Weinstein David S | Indole inhibitors of 15-lipoxygenase |
| WO2009042092A1 (en) | 2007-09-25 | 2009-04-02 | Merck & Co., Inc. | 2-aryl or heteroaryl indole derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101916443B1 (ko) | Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 | |
| EP3615534B1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| EP3697785B1 (en) | Imidazo-pyridine compounds as pad inhibitors | |
| ES2945314T3 (es) | Derivados de benzoimidazol como inhibidores de PAD4 | |
| EP2346878B1 (en) | Fused pyridine derivatives as kinase inhibitors | |
| KR20250067967A (ko) | 면역조절제로서 복소환형 화합물 | |
| CA3106513A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| TW202435884A (zh) | 用於抑制tnf受體1活性之環狀肽 | |
| HK40058586A (en) | Process for preparing fused pentacyclic imidazole derivatives and uses thereof as modulators of tnf activity | |
| HK40058586B (en) | Process for preparing fused pentacyclic imidazole derivatives and uses thereof as modulators of tnf activity | |
| HK40024466B (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| HK40024466A (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150226 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170725 Comment text: Request for Examination of Application |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180801 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20181101 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20181102 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20211026 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20211026 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20221017 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20221017 Start annual number: 5 End annual number: 5 |